Browse Drug Recalls
233 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 233 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 233 FDA drug recalls in NV.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| May 17, 2016 | Hydrogen Peroxide 3%, packaged in 10mL bottles, Rx only, Well Care Compound... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | ESTRADIOL VALERATE 40MG/ML, packaged in 1mL and 5mL vials, Rx only, Well Care... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | QUAD-MIX #4 (MOD), packaged in 5mL vials, Rx only, Well Care Compounding Phar... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | MB 12/HXB 12/FA/P5P/(LIDO 0.1 %), 2MG/2MCi/20MG/6.5MG/ML, packaged in 5mL via... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | ESTRADIOL VALERATE 10MG/ML, packaged in 1mL and 5mL vials, Rx only, Well Care... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | ITRACONAZOLE 0.2%/MUPIROCIN 0.2%/TRIAMCINOLONE 0.03% NASAL SPRAY, 15mL bottle... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | QUAD-MIX #1, packaged in 5mL vials, Rx only, Well Care Compounding Pharmacy L... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | PHENYLEPHERINE 0.5%, packaged in 5mL vials, Rx only, Well Care Compounding Ph... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | M.l.C. Methyl B12, 25 MG/50MG/25MG/1 MG/ML, packaged in 5mL vials, Rx only, W... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | LEVOCARNITINE 100MG/ML, packaged in 5mL vials, Rx only, Well Care Compoundin... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | 1-HCG 1000 IU/ML, packaged in 5mL and 10mL vials, Rx only, Well Care Compound... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | PHOSPHATIDYLCHOLINE/DEOXYCHOLIC ACID- 5%/4.75%, packaged in 10mL vials, Rx on... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | TRI-MIX # 6, packaged in 5mL vials, Rx only, Well Care Compounding Pharmacy L... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | HCG/METHYLCOBALAMIN/FOLIC ACID,1000IU/5MG/0.4MG/ML; packaged in 5 mL vials, R... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | 1-HCG 2000 IU/ML, packaged in 5mL vials, Rx only, Well Care Compounding Pharm... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | 17-0H PROGESTERONE 250MG/ML, packaged in 5mL vials, Rx only, Well Care Compou... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | GENTAMICIN 15 MG/ML Ophthalmic Solution, Sterile Droppers, Rx only, Well Care... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | M.l.C./B5/B6 25 MG/50MG/25MG/10MG/10MG/ML, packaged in 5mL vials, Rx only, W... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | METHYLCOBALAMIN/FOLIC ACID; 10MG/0.8MG/ML, packaged in 1mL and 5mL vials, Rx ... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | TRI-MIX # 2, packaged in 5mL vials, Rx only, Well Care Compounding Pharmacy L... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | M.l.C. 25MG/50MG/25MG/ML, packaged in 5mL vials, Rx only, Well Care Compoun... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | GLUTATHIONE 200MG/ML, packaged in 5mL vials, Well Care Compounding Pharmacy... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | L-GLUT/L-ARG/L-CARN; 25MG/100MG/200MG/ML, packaged in 5mL vials, Rx only, We... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | VANCOMYCIN 50MG/ML OPHTH SOLUTION; packaged in 10mL vial, Rx only, Well Care ... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | VITAMIN B COMPLEX # 3, packaged in 5mL vials, Rx only, Well Care Compoundin... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | TRI-MIX # 4, packaged in 5 mL vials, Rx only, Well Care Compounding Pharmacy ... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | SUPER TRI-MIX #1, packaged in 5mL vials, Rx only, Well Care Compounding Pharm... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | VITAMIN B COMPLEX # 1; packaged in 5mL vials, Rx only, Well Care Compoundin... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | METHYLCOBALAMIN 5MG/ML, packaged in 1mL and 5mL vials, Rx only, Well Care Com... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | CLOTRIMAZOLE 1%/ BETAMETHASONE DIPROPIONATE 0.05% OTIC SOLUTION, 15mL dropper... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | TRI-MIX # 1, packaged in 5mL vials, Rx only, Well Care Compounding Pharmacy L... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | ALPHA LIPOIC ACID 25MG/ML, packaged in 5mL vials, Rx only, Well Care Compound... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | SUPER TRI-MIX #4, packaged in 5mL vials, Rx only, Well Care Compounding Pha... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | MYERS' COCKTAIL, packaged in 37 mL vials, Rx only, Well Care Compounding Pha... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | ITRACONAZOLE 0.2%/MUPIROCIN 0.2% NASAL SPRAY; 30 mL Spray, Rx only, Well Car... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | METHYLCOBALAMIN 12.5MG/ML, packaged in 5mL vials, Rx only, Well Care Compound... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | QUAD-MIX #2, packaged in 5mL vial, Rx only, Well Care Compounding Pharmacy La... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | QUAD-MIX #3, packaged in 5mL vials, Rx only, Well Care Compounding Pharmacy L... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | METHYLCOBALAMIN 1 MG/ML, packaged in 1mL and 5mL vials, Rx only, Well Care Co... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | GLUTATHIONE 100MG/ML, packaged in 10 mL vials, Well Care Compounding Pharmacy... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| May 17, 2016 | ESTRADIOL CYPIONATE 10 MG/ML, packaged in 5mL vials, Rx only, Well Care Compo... | Lack of Assurance of Sterility: FDA inspection identified GMP violations potentially impacting pr... | Class II | Well Care Compounding Pharmacy |
| Mar 14, 2016 | Formula 2 (Papaverine 9 mg, Phentolamine 1 mg, Atropine 0.1 mg, PGE 10 mcg/mL... | Stability Does Not Support Expiry: manufactured with an active ingredient that expired before the... | Class II | Meditech Laboratories, Inc |
| Mar 14, 2016 | Formula 2 (Papaverine 9 mg, Phentolamine 1 mg, Atropine 0.1 mg, PGE 10 mcg/mL... | Superpotent Drug: one ingredient was found to be above assay specification. | Class II | Meditech Laboratories, Inc |
| Mar 14, 2016 | Formula 1 (Papaverine 1.8 mg, Phentolamine 0.2 mg, Atropine 0.02 mg, PGE 18 m... | Stability Does Not Support Expiry: manufactured with an active ingredient that expired before the... | Class II | Meditech Laboratories, Inc |
| Mar 14, 2016 | Formula 3 (Papaverine 20 mg, Phentolamine 3 mg, Atropine 0.2 mg, PGE 20 mcg/m... | Stability Does Not Support Expiry: manufactured with an active ingredient that expired before the... | Class II | Meditech Laboratories, Inc |
| Mar 14, 2016 | Formula 9 (Papaverine 0.9 mg, Phentolamine 0.1 mg, Atropine 0.01 mg, PGE 20 m... | Lack of Assurance of Sterility: incomplete or missing data regarding production. | Class II | Meditech Laboratories, Inc |
| Mar 14, 2016 | Formula 4 (Papaverine 18 mg, Phentolamine 2 mg, Atropine 0.2 mg/mL) Injection... | Lack of Assurance of Sterility: incomplete or missing data regarding production. | Class II | Meditech Laboratories, Inc |
| Mar 14, 2016 | Formula 0 (PGE 20 mcg/mL) Injection, 5 mL vials, Rx only, Meditech Laboratori... | Lack of Assurance of Sterility: incomplete or missing data regarding production. | Class II | Meditech Laboratories, Inc |
| Jan 26, 2015 | Compounded Plaquex, intravenous injection, 50 ML vial. Each ml contains: Ph... | Good Manufacturing Practices Deviations: The product has an active pharmaceutical ingredient from... | Class II | AnazaoHealth Corporation |
| Aug 28, 2014 | Dermatend Original, mole, wart and skin tag remover, For external use only, I... | Labeling: Labeling Bears Unapproved Claims; Dermatend is not FDA approved and therefore has not b... | Class II | Solace International Inc |
Frequently Asked Questions
When a drug safety issue is identified — through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks — the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.